Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for sepsis-induced coagulopathy (SIC)
ChiCTR2500105020Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2025
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in sepsis-associated coagulopathy (SAC) comparing Sulodexide with Placebo (5% glucose) (2 arms). Primary endpoint: ICU all-cause mortality. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sulodexide
03
Conditions
sepsis-associated coagulopathy (SAC)
Beyond the preview
Go deeper on ChiCTR2500105020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105020.